SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Peter Silsbee who wrote (2413)10/18/1997 10:56:00 PM
From: Izzy   of 6136
 
There are basically 2 classes of HIV: 1) drug sensitive [wild type}, 2) drug resistant [mutant type]. At issue is the capacity of the virus to mutate to strains resistant to currently available drugs. The 1/2 life of infected CD4+ cells is 2 days; lifespan of virus outside the cell is about 7 hrs.; 98% of the virus in circulation is a result of viral production in lymphoid tissue (not CD4 white cells). Therefore, for a satisfactory clinical outcome, drugs must be effective in reducing the rate of influx of HIV virions from the lymphatic system into the plasma circulation (viremia). This is where Viracept is the most effective PI (decreases capacity to mutate).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News